CMP : 830
Target Price : 872
For 2QFY2016, Aurobindo Pharma (APL) posted a decent set of results. The
company posted a sale of Rs3,280cr (v/s Rs3,320cr expected), a growth of 14.6%
yoy. Sales were driven by formulations (which constitute around 79.5% of sales),
which grew by 19.9% yoy. The key formulation segments like US, Europe &
ROW, and ARV posted a yoy growt..